background preloader

Pharmaceutical Medicine - Cancer Therapeutics

Facebook Twitter

Provocative Questions. Rare Cancers Australia - 2020 CanForum. Australia’s health system is among the best in the world.

Rare Cancers Australia - 2020 CanForum

While the overall picture of cancer in Australia currently points to extended survival, these improvements are not shared amongst all cancer types and will not ensue without evolving some fundamental aspects of our health system. The rapid pace of change brought about by emerging therapeutics and technology is challenging our previously well-equipped system. Over 550,000 Australians will die from cancer between now and 2030 if nothing changes. However, if we plan and do the work now to maximise new science and emerging technologies, we will save lives. Omico - Outsmarting Cancer Together - Omico. Guidelines for Formatting Gene and Protein Names. Release Date: January 30, 2014Category: Scientific WritingAuthor: Katherine A., Ph.D.

Guidelines for Formatting Gene and Protein Names

Within articles describing genetic studies, it is often difficult for readers to determine whether the authors are referring to a gene or its corresponding protein. This can be problematic when readers are trying to understand the details of complex molecular systems and the methodology used by the authors to probe those systems. To reduce this potential source of confusion for both peer reviewers and the larger audience of your published article, it is important to use accepted formatting conventions for gene and protein symbols in a consistent manner throughout your manuscript. National Strategic Action Plan for Blood Cancer June 2020. Global Cancer Observatory. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials - The Lancet Oncology.

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology - PubMed. New clinical trial designs in the era of precision medicine - PubMed. EG declares Advisory role for Roche, Janssen, NeoMed Therapeutics, Boehringer and Ellipses Pharma; Speaker's fee from MSD and Direct Research Funding from Novartis.

New clinical trial designs in the era of precision medicine - PubMed

RD declares Advisory role for Roche and Novartis; Speaker's fee from Roche, Symphogen, Ipsen, Amgen and Sanofi and Direct Research Funding from Merck. AP‐G has no conflicts to declare. IB declares Advisory role for Orion Pharma; Speaker's fee from BMS, AstraZeneca and Merck Serono; and Financial Support for clinical trials or contracted research for AstraZeneca, BMS, Celgene, Gliknik, GSK, Janssen, KURA, MSD, Novartis, Orion Pharma and Pfizer. Principles of radiotherapy - Oncology for Medical Students. Radiotherapy and multidisciplinary cancer care Radiotherapy can prolong survival, contribute to the preservation of organs affected by malignancy, provide palliation and improve patients’ quality of life.

Principles of radiotherapy - Oncology for Medical Students

Recent research shows that about 50% of patients with newly-diagnosed cancers (other than non-melanotic skin cancers) would benefit from radiotherapy[1]. One-quarter of these patients may need further treatment after relapse. The provision of a safe and effective radiation oncology service is complex. NCI Dictionary of Cancer Terms. Australia's health 2020. Australia’s health 2020 is AIHW’s 17th biennial flagship report on health.

Australia's health 2020

It explores topical health issues and brings together multiple data sources to serve as a report card on the health of Australians. The report considers health to be much more than the presence or absence of disease—health reflects the complex interactions of a person’s genetics, lifestyle and environment, and is fundamental to an individual’s wellbeing. PharmaVOICE TherapeuticDigest Oncology. Genomic and precision medicine : infectious and inflammatory disease - UNSW Alma.

Evaluating Literature for Oncology Data Gaps to Improve the Quality of Standard Response Letters: A Retrospective Review. Background: Medical information departments are responsible for maintaining standard response letters to address health care providers’ inquiries.

Evaluating Literature for Oncology Data Gaps to Improve the Quality of Standard Response Letters: A Retrospective Review

Several factors, including Food and Drug Administration regulations, insufficient diversity in clinical trials, and stringent exclusion criteria, might limit the information available to respond to unsolicited requests. However, if new data becomes available for an inquiry that was previously unanswered, it is not common practice for medical information departments to provide an updated response to health care providers. Therefore, the purpose of this study is to evaluate the impact of reviewing literature to provide an updated response to health care providers. Breast cancer drug approvals by the US FDA from 1949 to 2018. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. All.Can Australia launches national data from patient survey - All.Can.

(8) Sci Fi Series – Future Planet. All.Can patient survey - All.Can. Patient insights on cancer care: opportunities for improving efficiency Findings from the international All.Can patient survey The patient perspective is too often forgotten in considerations of how cancer care can be improved.

All.Can patient survey - All.Can

The All.Can patient survey gave us a unique opportunity to ask this question directly to those who have had personal experience of cancer. Almost 4,000 cancer patients and caregivers from more than 10 countries across the world responded to the survey to share their experiences. While most reported that their needs were sufficiently addressed during their care, they highlighted some specific areas where they encountered inefficiency. We have identified four key opportunities for improvement based on the responses to the survey: The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Cancer preparedness around the world. HEAT: Health Evaluations + applied Therapeutics. Database Access - UNSW Library. SCprimer2009. Centre for Oncology Education and Research Translation - Cancer Institute NSW.

Implications of CRISPR-Based Germline Engineering for Cancer Survivors - Gregory Katz, Peter J. Pitts, 2017. Database Access - UNSW Library. Paper: Evaluating Hematologist's Knowledge of CAR T-Cell Therapy in Hematologic Malignancies. Loxo Oncology's cancer drug wins a pioneering FDA approval. A biotech company called Loxo Oncology won a first-of-its-kind approval from the Food and Drug Administration on Monday, bringing to market a cancer drug that can treat an array of tumors regardless of where they are in the body.

Loxo Oncology's cancer drug wins a pioneering FDA approval

But upending regulatory tradition may have been the easy part, as Loxo’s hopes of making money depend on scouring the world for patients with a rare genetic mutation. The drug, larotrectinib, is designed to kill off tumors by attacking a protein called TRK, which becomes hyperactive in people with certain genetic mutations. Whereas nearly all cancer drugs are approved to fight malignancies in the lung, breast, or pancreas, Loxo’s therapy is cleared for any advanced cancer that expresses TRK, making it the first drug developed as a tumor-agnostic treatment, according to the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free! What is it? What's included? National Rare Disease Framework. Government Response. Cancer Genes. The cell division process is dependent on a tightly controlled sequence of events.

Cancer Genes

These events are dependent on the proper levels of transcriptionThe production of an RNA molecule from a DNA template. An RNA copy of a gene is produced by an enzyme, RNA polymerase. The RNA produced can either be used directly in the cell or can be used to direct the production of a protein through the process of translation. Nomenclature schemes advanced therapies 201707. Revised mAb nomenclature scheme. Epigenetic regulation and cancer (Review) 1.

Epigenetic regulation and cancer (Review)

Epigenetic mechanisms In the eukaryotic nucleus, DNA is compacted into a chromatin structure with the nucleosome as the basic unit, in which histone octamer is surrounded by the 147 bases of DNA for 1.7 laps. The histone octamer includes two elements of the core histone (H3, H4, H2A and H2B) (1). Cancer Epigenetics. Pharmaceutical Benefits Scheme (PBS) Page last updated: 10 August 2018 Public submissions to the August 2018 PBAC meeting regarding PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types are now available. Please direct any queries to the PBAC Secretariat via email to PBAC@health.gov.au. Public Submissions The consultation process for the August 2018 PBAC special meeting - PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types closed on 29 June 2018. The Department appreciates the contribution of all organisations and individuals who made a submission.

Medicines in Development for Cancer 2018 Report. To download the full report, click here. In recent decades, substantial progress has been made in the fight against cancer. Since peaking in the 1990s, cancer death rates have declined 26 percent, leading to more than 2.3 million cancer deaths avoided. IFOM. Surgical Oncology: The Basics. What is Surgical Oncology? Surgery as a medical field has been changing rapidly since the late 1800s, in large part thanks to the development of safe and effective anesthesia. Surgical oncology is a specialty that focuses on the surgical treatment of a variety of tumors. Ephraim McDowell did the first reported resection of an ovarian tumor in 1809, but as early as the 7th century, ancient Egyptians described techniques for removing breast tumors. Today, general surgeons can pursue additional training after their residency in the form of a surgical oncology fellowship. However, a surgeon does not have to do a surgical oncology fellowship in order to be a surgical oncologist.

What is the Role of Surgery? Surgery is the oldest form of cancer treatment, and for most patients, part of the curative plan includes surgery. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Reovirus in cancer therapy: an evidence-based review. Going viral with cancer immunotherapy. Cancer Today. The methods of estimation are country-specific, and the quality of each estimation depends on the quality and amount of the information available that each country.

In theory, there are as many methods as countries, and because of the variety and complexity of these methods, an overall quality score for the incidence and mortality estimates combined is almost impossible to determine. Incidence. Pharmacovigilance in oncology: evaluation of current practice and future perspectives. - PubMed - NCBI. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views. - PubMed - NCBI. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines: Journal of Clinical Oncology: Vol 36, No 18. Rare Cancers Australia - About The Knowledgebase. Cancer Types The RCA Clinical Advisory Board (CAB) is comprised of senior health professionals who work within the oncology sector.

The majority of information contained within the Cancer Types directory is courtesy of www.cancer.gov, the US Government’s official cancer website. This information has been reproduced with the permission of the National Cancer Institute. Information sourced from this website is naturalised so that it conforms to Australian spelling and grammar conventions before it is posted to the RCA KnowledgeBase. Cancer sciences. Master of Cancer Sciences » VCCC. Database Access - UNSW Library. CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY.

Artificial Intelligence in Oncology: Fantasy or Reality? What Outcomes Matter in Cancer? A Literature Review. s41568 018 0021 8. The future of oncology. Gene editing tool may raise cancer risk in cells, scientists warn. Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII) Bmj. Untitled. Cancer immunotherapy. Toxicity profiles of immunotherapy. JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page. Abstract Immunotherapies are changing the landscape of advanced solid tumor treatment.

Cancer information and support - Cancer Council Australia. Problem loading page. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand. Evaluating Current and Emerging Strategies Using Checkpoint Inhibitors in the Fight Against Advanced/Metastatic Lung Cancer. A Look at How CAR-T Cell Therapy Works. Untitled. NCCN Radiation Therapy Compendium. NCCN Guidelines® & Clinical Resources About the NCCN Radiation Therapy Compendium™ Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Review highlights potential of cancer immunotherapy plus targeted therapy.

The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests "we are finally poised to deliver curative therapies to cancer patients," researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell. "To support this goal and accelerate these efforts, changes in directions of research support and funding may be required," co-authors Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology, and Jim Allison, Ph.D., chair of Immunology, said in the review.

The review, titled "Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential," covers the strengths and weaknesses of the two forms of therapy and notes how their combination could be particularly potent. CONCERT. Immunotherapy of cancer. Joseph A Trapani Phillip K Darcy. Trial Detail - UK Clinical Trial Gateway. Glossary of Terms/Common Abbreviations in Oncology. Database Access - UNSW Library. 125514s014lbl. Press Announcements > FDA approves first cancer treatment for any solid tumor with a specific genetic feature.

The U.S. FDA leaps into precision medicine — with caveats. A one-two punch for pancreatic cancer: ‘softening’ tumours before chemo. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. 'So what if my results say I'm doing better? I'm still dying – just not right now'